Core Viewpoint - Ascentage Pharma has received investigational new drug (IND) application clearance for its novel BTK-targeted protein degrader, APG-3288, from the China Center for Drug Evaluation (CDE), following similar clearance from the U.S. FDA, marking a significant milestone in its clinical development for patients with relapsed/refractory hematologic malignancies [1][6]. Group 1: Drug Development and Clinical Trials - APG-3288 is set to enter a multicenter, open-label Phase I study to evaluate its safety, tolerability, pharmacokinetic profile, and preliminary efficacy in patients with relapsed/refractory hematologic malignancies [2]. - The IND clearance for APG-3288 enhances Ascentage Pharma's pipeline in hematologic malignancies, complementing existing products like Olverembatinib and Lisaftoclax, which have already been approved in China [5]. Group 2: Mechanism of Action and Innovation - APG-3288 utilizes Ascentage Pharma's proprietary PROTAC technology to induce the degradation of BTK, overcoming resistance associated with conventional BTK inhibitors by blocking the BCR-BTK signaling axis at its source [4]. - The drug is designed to provide a novel therapeutic strategy by inducing rapid and sustained degradation of both wild-type BTK and multiple BTK mutants, addressing the urgent clinical need for new treatment options in B-cell malignancies [3][4]. Group 3: Company Background and Strategy - Ascentage Pharma is a global biopharmaceutical company focused on developing innovative therapies for cancer, with a strong presence in hematologic malignancies and a diverse pipeline of drug candidates [8]. - The company has established partnerships with leading biotechnology and pharmaceutical firms, enhancing its research and development capabilities and expanding its global reach [11].

Core Viewpoint - Ascentage Pharma has received investigational new drug (IND) application clearance for its novel BTK-targeted protein degrader, APG-3288, from both the U.S. FDA and the China CDE, marking a significant milestone in its clinical development for treating relapsed/refractory hematologic malignancies [1][6]. Group 1: Drug Development and Clinical Trials - APG-3288 is set to enter a multicenter, open-label Phase I study to evaluate its safety, tolerability, pharmacokinetic profile, and preliminary efficacy in patients with relapsed/refractory hematologic malignancies [2]. - The IND clearance from the China CDE follows the earlier approval from the U.S. FDA, indicating strong global development capabilities in targeted protein degradation [1][6]. Group 2: Mechanism of Action and Clinical Need - APG-3288 is a highly potent and selective BTK degrader developed using Ascentage Pharma's proprietary PROTAC technology, designed to induce degradation of both wild-type BTK and multiple BTK mutants associated with resistance to existing BTK inhibitors [4]. - There is a significant clinical need for new drugs with novel mechanisms of action due to the limitations of current BTK inhibitors, which often face issues of acquired resistance [3][4]. Group 3: Company Background and Pipeline - Ascentage Pharma has established a strong presence in the field of hematologic malignancies, with a portfolio that includes approved products like Olverembatinib and Lisaftoclax, enhancing its pipeline in this area [5][9]. - The company is focused on developing innovative therapies to address unmet medical needs in cancer, leveraging its robust R&D capabilities and global partnerships with leading biotechnology and pharmaceutical companies [8][11].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 亞盛醫藥集團 | | | | | | 呈交日期: | 2026年2月5日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06855 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | 0.0 ...

Core Viewpoint - The article discusses the significant progress in China's innovative drug development, highlighting the increase in the number of new drugs approved and the growing competitiveness of Chinese pharmaceutical companies in both domestic and international markets [4][16]. Group 1: Growth of Innovative Drugs - In 2024, the number of domestically developed Class 1 new drugs in China reached 40, a substantial increase from just 9 in 2018 [2][3][4]. - Since the beginning of the 14th Five-Year Plan, 113 innovative drugs have been approved, which is 2.8 times the number approved during the 13th Five-Year Plan [4]. - As of August 2024, there are 910 new drugs available in China, indicating a robust growth in the pharmaceutical market [6]. Group 2: Clinical Trials and Breakthroughs - In a head-to-head clinical trial, the drug Ivoris (依沃西单抗) developed by Kangfang Biopharma outperformed the global best-selling cancer drug, Pembrolizumab (K drug), marking a significant achievement for Chinese innovation [7][9]. - The global sales of Pembrolizumab reached $29.482 billion in 2024, underscoring the competitive landscape [8]. Group 3: Market Dynamics and International Expansion - Chinese innovative drugs are not only performing well domestically but are also gaining traction in international markets, with products like Sidakio (西达基奥仑赛) achieving $1.596 billion in cumulative sales since its launch [12][13]. - The total transaction scale of technology licensing by Chinese pharmaceutical companies exceeded $34 billion in 2024, indicating a shift towards international collaboration [14][15]. Group 4: R&D Landscape and Challenges - As of August 2024, there are 5,380 new drug candidates in development in China, accounting for over one-third of the global pipeline [18]. - The average cost of developing an innovative drug is around $1 billion, with a typical development timeline of 10 years [20][21]. - The efficiency of drug development in China is improving, with preclinical phases taking 12-20 months compared to 24-36 months internationally [23]. Group 5: Policy Support and Ecosystem - The Chinese government has implemented various policies since 2008 to support innovative drug development, including expedited approval processes and financial incentives [28][29]. - The combination of government support, industry collaboration, and technological advancements is creating a conducive environment for innovation in the pharmaceutical sector [41]. Group 6: Future Outlook - The article emphasizes that the development of innovative drugs in China has made significant strides over the past decade, transitioning from imitation to innovation [42]. - The government's continued support for innovative drugs is expected to enhance the industry's growth and provide hope for patients [42].

点击蓝字，关注我们 今日上午港股 1 . 加密货币概念股早盘再度下跌，截至发稿， 迷策略(02440)跌4.76%，雄岸科技(01647)跌1.37%，欧 科云链(01499)跌0.58% 。 消息面上，周二，比特币一度跌破7.3万美元，跌破了2025年4月7日特朗普 公布对等关税后所创的年内低点。"大空头"巴里警告称，若比特币价格进一步下跌可能会迅速加剧主 要持有者的资产负债表压力，迫使整个加密货币生态系统进行抛售，并引发大范围的价值崩盘。 2 . AI新技术冲击软件股， 聚水潭(06687)今早一度跌近13%，创上市以来新低，截至发稿跌9.27% 。 消息面上，周二，由AI初创巨头Anthropic推出的新型自动化工具引发了市场对软件股的恐慌性抛售， 创下去年4月以来跌幅最大的一天。分析师指出，AI进展的预期已发生质变：从最初认为AI能"助力增 长"，转向质疑AI是否会"彻底取代"传统订阅模式。 3 . 高地股份(01676)盘中跌近40% 。消息面上，香港联交所最新资料显示，1月15日，高地股份股东将 股票由凯基证券亚洲转入富途证券国际香港，转仓市值2095.26万港元，占比13.51%。高地股份发布 ...

Core Viewpoint - Ascentage Pharma-B (06855) saw its stock rise over 3%, currently trading at 47.44 HKD with a transaction volume of 31.5152 million HKD, following the announcement of clinical approval for its new drug APG-3288 by the China National Medical Products Administration (NMPA) [1] Group 1: Drug Approval and Development - The China NMPA's Center for Drug Evaluation (CDE) has publicly announced the clinical approval of Ascentage Pharma's first-class new drug APG-3288, which is intended for the treatment of relapsed/refractory hematologic malignancies [1] - APG-3288 is a next-generation BTK-targeted protein degradation therapy developed by Ascentage Pharma, which had already received clinical approval in the United States in August for treating relapsed/refractory B-cell malignancies [1] Group 2: Drug Characteristics and Potential - APG-3288 is the company's first novel, highly efficient, and selective BTK degrader, which promotes the formation of a ternary complex leading to BTK degradation via the proteasome [1] - Preclinical studies indicate that APG-3288 demonstrates stronger BTK degradation capability, higher selectivity, and superior pharmacokinetic characteristics compared to other BTK degraders in development, showcasing significant potential [1]

Core Viewpoint - Ascentage Pharma-B (06855) has seen its stock price increase by over 3%, currently trading at 47.44 HKD with a transaction volume of 31.5152 million HKD, following the approval of its new drug APG-3288 for clinical trials by the China National Medical Products Administration (NMPA) [1] Group 1: Drug Approval and Development - The China National Medical Products Administration (NMPA) has publicly announced the approval of Ascentage Pharma's first-class new drug APG-3288 for clinical trials, aimed at treating relapsed/refractory hematologic malignancies [1] - APG-3288 is a next-generation BTK-targeted protein degradation therapy developed by Ascentage Pharma, which has already received clinical approval in the United States in August for treating relapsed/refractory B-cell malignancies [1] Group 2: Drug Characteristics and Potential - APG-3288 is the first novel, highly efficient, and selective BTK degrader independently developed by Ascentage Pharma, which promotes the formation of a ternary complex leading to BTK degradation via the proteasome [1] - Preclinical research results indicate that APG-3288 exhibits stronger BTK degradation capability, higher selectivity, and superior pharmacokinetic characteristics compared to other BTK degraders in development, showcasing significant potential [1]

Core Insights - The JPMorgan Global Healthcare Conference serves as a significant platform for the biopharmaceutical industry, influencing capital flows and industry dynamics for the year ahead [1] - This year's conference highlighted the increasing presence of Chinese biotech companies, marking a shift from being mere spectators to key players in the global market [2][3] Group 1: Chinese Biotech Companies - Seven Chinese companies, including WuXi AppTec and BeiGene, presented on the main stage, with an additional 17 companies showcasing in the Asia-Pacific session [2] - The transformation of Chinese companies from the periphery to the center of the conference reflects their substantial innovation value, evidenced by numerous licensing deals announced during the event [3] Group 2: Licensing Deals and Collaborations - Notable licensing agreements included a $650 million upfront payment from AbbVie to Rongchang Biopharma for the global rights to its PD-1/VEGF dual-specific antibody, with a total potential deal value of up to $5.6 billion [3] - Other significant collaborations involved Zhongsheng Peptide and Sai Shen Pharmaceutical partnering with Novartis, with the latter's deal valued at approximately $1.665 billion [3] Group 3: MNCs and Market Dynamics - The cautious approach of multinational corporations (MNCs) towards acquisitions is driven by the impending "patent cliff," with over $320 billion in market potential products set to lose patent protection in the next decade [3][5] - MNCs are increasingly favoring "asset-based acquisitions" over full company buyouts, allowing them to efficiently acquire core assets without the burdens of integrating entire companies [4] Group 4: AI in Drug Development - AI's integration into drug development emerged as a central theme, with Eli Lilly and NVIDIA announcing a partnership to establish a $1 billion AI innovation lab aimed at addressing long-standing challenges in the pharmaceutical industry [5][6] - The acquisition of Modella AI by AstraZeneca further emphasizes the growing importance of AI in enhancing drug discovery and clinical development processes [6] Group 5: Future Outlook - The 2026 JPM conference is expected to reflect a new paradigm where Chinese innovation becomes essential, and AI evolves from a supportive tool to a foundational infrastructure in drug development [8][9]

北京时间2026年1月22日，北京中喜文化传媒有限公司向美国证券交易委员会重新递交了上市申请，募资额大幅提升至约1875万美元，这标志着中概股赴美 上市的融资策略正在发生微妙变化。 2026年1月23日，搜狐报道称，中喜文化重新向美国SEC递交上市申请，拟以每股4至5美元发行375万股。而在此前的招股书中，该公司仅计划发行125万 股。 中喜文化的策略转变并非孤例。自2025年以来，美国市场对中国企业的态度发生了深刻变化，赴美上市规则正在全面收紧。 截至2025年上半年，中喜文化营收为1676万美元，净利润238万美元，主要股东包括冯彬和何晓云等人。其业务范围横跨传统电视节目发行和智能设备投屏 广告代理。 中喜文化并非唯一在2025年下半年调整IPO策略的中国企业。东方财富网报道称，当年6月13日以来，共有金特安、中喜文化、网塑科技等11家中企更新了 招股书。 从这些企业的募资规模看，多集中在500万至1500万美元区间。值得注意的是，当时中喜文化仍计划发行125万股，募资500万至625万美元。 这一波中概股赴美上市潮与2024年形成了鲜明对比。富途发布的2025年上半年IPO报告指出，2024年中国企业赴 ...

Core Viewpoint - The efficiency of Chinese innovative pharmaceutical companies in research and development is putting pressure on American firms, leading to a shift in strategy where multinational companies are cutting internal R&D budgets to invest in Chinese companies' pipelines [1][7]. Group 1: JPM Conference Insights - The 2026 JPM conference saw a significant presence of Chinese innovative pharmaceutical executives and investors, reflecting a positive outlook compared to previous years, with multinational companies openly expressing interest in Chinese assets [2][4]. - Chinese companies are no longer satisfied with merely licensing patents; they seek deeper involvement in clinical development and commercialization in international markets [3][10]. - The FDA's officials acknowledged the R&D efficiency of Chinese companies and suggested using AI to improve approval processes, indicating a more collaborative approach rather than a protectionist stance [3][6]. Group 2: Market Trends and Stock Performance - Following a surge in business development (BD) transactions in 2025, the stock prices of Chinese innovative pharmaceutical companies saw a significant increase, but there was a market correction starting in September 2025, with the Hang Seng Innovation Drug Index dropping over 20% by January 2026 [3][12]. - The participation of seven Chinese pharmaceutical companies in the main stage of JPM is a sign of increasing recognition and influence in the international market [12]. Group 3: Strategic Shifts in Collaboration - There is a growing trend among Chinese pharmaceutical companies to engage in deeper collaborations, such as the NewCo model, which allows for shared operations and deeper partnerships with American firms [10][11]. - American biotech companies are considering establishing NewCo in China to leverage the country's advantages in R&D efficiency and cost [11]. Group 4: Competitive Landscape and Future Outlook - The competitive landscape is shifting, with Chinese companies focusing on unmet clinical needs and exploring new therapeutic areas beyond traditional targets, such as liver diseases [11]. - Multinational companies are actively seeking new opportunities due to impending patent cliffs, with significant interest in mergers and acquisitions to bolster their pipelines [14][15]. - PwC's report indicates that patent expirations could risk $47 billion in drug sales over the next four years, prompting increased acquisition activities in the pharmaceutical sector [16].